SPOTLIGHT -
Olaparib antitumor activity sustained across HRR gene subtypes in mCRPC
“These findings support the importance of genomic testing to identify patients eligible to consider olaparib treatment,” said Johann de Bono, MB CHB, PhD, MSC.
FDA grants priority review to Vicineum for NMIBC
The safety and efficacy of the locally administered fusion protein were assessed in the phase 3 VISTA trial.
Pivotal data for PSMA PET imaging agent 18F-DCFPyL shared as FDA weighs approval in prostate cancer
The FDA is scheduled to make a decision on a new drug application for 18F-DCFPyL on or before May 28, 2021.
Apalutamide plus abiraterone reduces risk of progression in mCRPC
There was a trend toward better overall survival outcomes with the apalutamide/abiraterone combination in certain prespecified biomarker subgroups.
Study results may help target anti–PD-1/PD-L1 agents to appropriate RCC patients
The study assessed factors associated with survival outcomes in patients with metastatic clear cell renal cell carcinoma receiving immune checkpoint inhibitors.
Add-on vibegron effective for OAB in men receiving standard BPH treatments
The investigators also determined independent factors affecting the efficacy of vibegron in this setting.
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA new drug application filing expected by the end of 2021.
Novel minimally-invasive BPH device shows early promise
The XFLO Expander System provided patients with symptom relief while preserving sexual function.
Novel focal ablation system proceeds through prostate cancer pipeline
A streamline procedure allows treatment with the NanoTherm therapy system for focal ablation to be completed within 1 day.
Darolutamide plus ADT explored in phase 3 mHSPC trial
Darolutamide is currently approved by the FDA for the treatment of men with nonmetastatic castration-resistant prostate cancer.
MRI-guided HIFU shows strong potential in localized prostate cancer
MRI-guided focused ultrasound ablation was highly effective with minimal side effects.
Frontline pembrolizumab monotherapy active across kidney cancer subtypes
Published data show the PD-1 inhibitor induced strong antitumor activity in patients with both advanced clear cell renal cell carcinoma (ccRCC) and advanced non-ccRCC.
Shorter radiation regimen lowers risk of bladder cancer recurrence
A 4-week hypofractionated radiotherapy course was associated with a lower risk of bladder cancer recurrence compared with a 6.5-week standard treatment course.
First European patient treated for urethral stricture with novel drug-coated balloon catheter
The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.
Prophylactic whole-pelvic radiotherapy provides benefit in high-risk prostate cancer
In a phase 3 trial, biochemical failure-free survival and disease-free survival were improved with prophylactic whole-pelvic radiotherapy versus prostate-only radiotherapy.
Testicular cancer linked to high long-term mental health burden
The rates of mental healthcare use were significantly higher for patients versus healthy controls during diagnosis, treatment, and long-term survivorship.
ASCO publishes guideline update for initial management of noncastrate advanced prostate cancer
Abiraterone acetate, enzalutamide, and apalutamide are highlighted among the standards of care for initial treatment.
Prior BPH surgery does not affect oncologic outcomes with prostate cryoablation
The risks of erectile dysfunction or rectourethral fistula post-cryosurgery were also not increased by prior surgical interventional therapy for benign prostatic hyperplasia.
Study supports shorter radiation regimen in high-risk prostate cancer
Stereotactic body radiotherapy produced similar efficacy without added toxicity compared with standard radiation in men with advanced prostate cancer.
Real-World data show utility of 18F-fluciclovine PET/CT in biochemically recurrent prostate cancer
Twelve percent of patients with negative results on conventional imaging had lesion localization on 18F-fluciclovine PET.
First US patients dosed with novel imaging radiopharmaceutical for renal cell carcinoma
The phase 3 ZIRCON trial is assessing TLX250-CDx as a noninvasive tool to identify clear cell renal cell carcinoma in patients with indeterminate renal masses.
Avelumab approved in EU for frontline maintenance in bladder cancer
The PD-L1 inhibitor was approved based on data from the phase 3 JAVELIN Bladder 100 study.
FDA approves nivolumab/cabozantinib combo for frontline kidney cancer
The approval is based on data from the phase 3 CheckMate-9ER trial.
Specialty pharmacy designated as provider of relugolix for prostate cancer
The GnRH receptor antagonist was approved by the FDA in December 2020 for the treatment of patients with advanced prostate cancer.
Focal radiation boost improves outcomes in prostate cancer
The boost improved biochemical disease-free survival without negatively affecting safety and quality of life.
Prostate cancer–related suicide declined over the past 20 years
The trend in prostate cancer aligns with an overall decline in cancer-related suicide across all tumor types.
ADT does not lower COVID-19 risk in men with prostate cancer
The study contradicts the findings from an Italian study published in 2020.
FDA grants Fast Track designation to novel treatment for UTUC
The investigational padeliporfin ImPACT platform involves the intravenous delivery of the photosensitive drug padeliporfin, which is then activated by a non-thermal light delivery system.
Decision regret worse among African American men with prostate cancer
Higher medical mistrust and concerns about masculinity likely contribute to the increased decision regret.
AI tool shows promise in predicting biochemical recurrence in prostate cancer
The integrated radiomic-clinicopathologic nomogram (RadClip) was a better prognosticator of biochemical recurrence-free survival and adverse pathology than other standard tools.